Valuation: Harrow, Inc.

Market Cap 1.6B 1.4B 1.29B 1.19B 2.27B 153B 2.3B 15.46B 6.06B 75.01B 6.01B 5.88B 260B P/E 2026 *
173x
P/E 2027 * 18.6x
Enterprise Value 1.6B 1.4B 1.29B 1.19B 2.27B 153B 2.3B 15.46B 6.06B 75.01B 6.01B 5.88B 260B EV / Sales 2026 *
4.59x
EV / Sales 2027 * 3.1x
Free-Float
84.53%
Yield 2026 *
-
Yield 2027 * -
1 day-4.75%
1 week+0.44%
Current month+1.08%
1 month+28.30%
3 months+15.12%
6 months-8.23%
Current year-12.39%
1 week 42.59
Extreme 42.59
46.62
1 month 35.5
Extreme 35.5
46.62
Current year 28.54
Extreme 28.5401
54.85
1 year 28.54
Extreme 28.5401
54.85
3 years 7.6
Extreme 7.6
59.23
5 years 5.4
Extreme 5.4
59.23
10 years 1.35
Extreme 1.35
59.23
Manager TitleAgeSince
Chief Executive Officer 53 2011-12-16
President 43 2025-08-20
Compliance Officer - 2023-09-30
Director TitleAgeSince
Chairman 53 2021-08-18
Director/Board Member 57 2022-03-30
Director/Board Member 71 2024-01-25
Date Insider Type Main position Quantity % Market Cap.
06-17Free

Director

5,248 0.0141%
06-17Free

Director

5,248 0.0141%
06-17Free

Director

5,248 0.0141%
Change 5-day change 1-year change 3-year change Capi.($)
-4.75%+0.44%+35.60%+135.88% 1.68B
+0.09%+0.25%+54.65%+169.19% 1,084B
-1.63%-1.50%+65.79%+62.70% 634B
-1.12%-4.27%+31.10%+84.44% 447B
+0.18%-1.76%+29.04%+26.51% 330B
-6.22%-3.61%+29.15%+32.09% 295B
-1.27%-2.91%+27.42%+46.39% 285B
-0.93%-1.19%-28.85%-40.38% 218B
-1.19%-2.81%+22.63%+66.30% 199B
-0.72%+2.72%+19.07%+81.19% 169B
Average -1.63%-0.26%+28.56%+66.43% 366.15B
Weighted average by Cap. -0.91%-0.88%+38.87%+84.83%

Financials

2026 *2027 *
Net sales 348M 305M 281M 260M 494M 33.25B 502M 3.37B 1.32B 16.33B 1.31B 1.28B 56.56B 516M 451M 416M 385M 730M 49.22B 743M 4.98B 1.95B 24.17B 1.94B 1.89B 83.72B
Net income 9.76M 8.54M 7.87M 7.29M 13.83M 932M 14.06M 94.29M 36.96M 457M 36.64M 35.85M 1.58B 92.89M 81.26M 74.93M 69.33M 132M 8.87B 134M 897M 352M 4.35B 349M 341M 15.08B
Net Debt - -
Logo Harrow, Inc.
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Employees
373
Date Price Change Volume
26-07-09 US$42.93 -4.75% 540,060
26-07-08 US$45.07 -2.34% 534,030
26-07-07 US$46.15 +2.72% 802,535
26-07-06 US$44.93 +5.12% 949,421
26-07-02 US$42.74 -0.60% 492,619
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
42.93USD
Average target price
67.75USD
Spread / Average Target
+57.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HROW Stock